Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice Tsang Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015
Cited by 636 works. doi:10.1016/s1470-2045(15)00488-x
Authors
- Alice Tsang Shaw
- Leena Gandhi
- Shirish M. Gadgeel
- Gregory J. Riely
- Jeremy Paul Cetnar
- Howard West
- D. Ross Camidge
- Mark A. Socinski
- Alberto Chiappori
- Tarek M. Mekhail
- Bo H. Chao
- Hossein Borghaei
- Kathryn Ann Gold
- Ali Hassan Zeaiter
- Walter Bordogna
- Bogdana I Balas
- Óscar Puig
- Volkmar Henschel
- Sai‐Hong Ignatius Ou
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors